Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/31621
Title: Favipiravir in early symptomatic COVID-19, a randomised placebo-controlled trial.
Austin Authors: McMahon, James H;Lau, Jillian S Y;Coldham, Anna;Roney, Janine;Hagenauer, Michelle;Price, Sally;Bryant, Mellissa;Garlick, Jill;Paterson, Anne;Lee, Sue J;O'Bryan, Jess;Hearps, Anna;Tachedjian, Gilda;Pinskier, Henry;Phillips, Cameron;Garrow, Stuart;Pinskier, Nathan;Melvin, Robert;Blakeway, Luke;Wisniewski, Jessica A;Byers, Sally;Badoordeen, Gnei Z;Pereira, Stephanie;Pragastis, Katherine;Trubiano, Jason ;Chua, Kyra Y L ;Kainer, Marion;Molton, James S;Gardiner, Bradley J;Pierce, Anna B;Cheng, Allen;Rogers, Benjamin A;Peleg, Anton Y
Affiliation: Department of Infectious Diseases, Alfred Hospital and Central Clinical School, Monash University, Melbourne, Australia.
Department of Infectious Diseases, Monash Medical Centre, Melbourne, Australia.
Life Sciences Discipline, Burnet Institute, Melbourne, Australia.
Onsite Doctor and OSD.Care, Melbourne, Australia.
Department of Emergency Medicine, Alfred Hospital, Melbourne, Australia.
Department of Infectious Diseases, Alfred Hospital and Central Clinical School, Monash University, Melbourne, Australia.
Infectious Diseases
Department of Infectious Diseases, Western Health, Melbourne, Australia.
Issue Date: Dec-2022
Date: 2022
Publication information: EClinicalMedicine 2022; 54
Abstract: Well tolerated antivirals administered early in the course of COVID-19 infection when the viremia is highest could prevent progression to severe disease. Favipiravir inhibits SARS-CoV-2 viral replication in vitro with evidence of clinical benefit in open label trials. Placebo controlled studies of people with early symptomatic COVID-19 with regular assessments of SARS-CoV-2 viral load can determine if it has an antiviral effect and improves clinical outcomes.
URI: https://ahro.austin.org.au/austinjspui/handle/1/31621
DOI: 10.1016/j.eclinm.2022.101703
ORCID: 
Journal: EClinicalMedicine
Start page: 101703
PubMed URL: 36284645
ISSN: 2589-5370
Type: Journal Article
Subjects: COVID-19
Favipiravir
Randomised clinical trial
Appears in Collections:Journal articles

Show full item record

Page view(s)

40
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.